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1  | INTRODUC TION
The coronavirus disease 2019 (COVID-19) is a new infectious dis-
ease caused by severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2), which has reached pandemic status. Although clinical 
manifestations in patients with COVID-19 are mainly related to the 
respiratory system, cardiovascular complications have also been iden-
tified in the earliest reported cases from Wuhan, the epicenter of the 
outbreak.1–3 COVID-19 can significantly affect cardiac function and in-
duce cardiac injury. And the latter is associated with increased disease 
 
Received: 9 June 2020  |  Revised: 24 June 2020  |  Accepted: 30 June 2020
DOI: 10.1002/joa3.12405  
C L I N I C A L  R E V I E W
Cardiac arrhythmias in patients with COVID-19
Yueying Wang MS1 |   Zhaojia Wang MS1 |   Gary Tse PhD, FESC, FACC1  |   Lin Zhang MD, PhD2 | 
Elaine Y. Wan MD, FACC, FAHA3 |   Yutao Guo MD, PhD4 |   Gregory Y. H. Lip MD4,5  |   
Guangping Li MD, PhD1 |   Zhibing Lu MD, PhD2 |   Tong Liu MD, PhD1
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society
1Tianjin Key Laboratory of Ionic-Molecular 
Function of Cardiovascular Disease, 
Department of Cardiology, Tianjin Institute 
of Cardiology, Second Hospital of Tianjin 
Medical University, Tianjin, People’s 
Republic of China
2Department of Cardiology, Zhongnan 
Hospital of Wuhan University, Wuhan, 
People’s Republic of China
3Division of Cardiology, Department of 
Medicine, Vagelos College of Physicians and 
Surgeons, Columbia University, New York, 
NY, USA
4Medical School of Chinese PLA, 
Department of Cardiology, Chinese PLA 
General Hospital, Beijing, China
5Liverpool Centre for Cardiovascular 
Sciences, University of Liverpool and 
Liverpool Heart & Chest Hospital, Liverpool, 
UK
Correspondence
Tong Liu, Tianjin Key Laboratory of Ionic-
Molecular Function of Cardiovascular 
disease, Department of Cardiology, Tianjin 
Institute of Cardiology, Second Hospital of 
Tianjin Medical University, No. 23, Pingjiang 
Road, Hexi District, Tianjin 300211, People’s 
Republic of China.
Email: liutongdoc@126.com
Zhibing Lu, Department of Cardiology, 
Zhongnan Hospital of Wuhan University, 
East Lake Road, Wuchang District, Wuhan 
430071, Hubei, People’s Republic of China.
Email: luzhibing222@163.com
Abstract
The emergence of coronavirus disease 2019 (COVID-19), caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a major global pub-
lic health concern. Although SARS-CoV-2 causes primarily respiratory problems, 
concurrent cardiac injury cannot be ignored since it may be an independent predic-
tor for adverse outcomes. Cardiac arrhythmias are often observed in patients with 
COVID-19, especially in severe cases, and more likely contribute to the high risk of 
adverse outcomes. Arrhythmias should be regarded as one of the main complications 
of COVID-19. Mechanistically, a number of ion channels can be adversely affected in 
COVID-19, leading to alterations in cardiac conduction and/or repolarization proper-
ties, as well as calcium handling, which can predispose to cardiac arrhythmogenesis. 
In addition, several antimicrobials that are currently used as potential therapeutic 
agents for COVID-19, such as chloroquine, hydroxychloroquine and azithromycin, 
have uncertain benefit, and yet may induce electrocardiographic QT prolongation 
with potential ventricular pro-arrhythmic effects. Continuous electrocardiogram 
monitoring, accurate and prompt recognition of arrhythmias are important. The pre-
sent review focuses on cardiac arrhythmias in patients with COVID-19, its underlying 
mechanisms, and proposed preventive and therapeutic strategies.
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severity and fatal outcomes.4–7 A variety of pro-inflammatory media-
tors play a key role in the pathophysiology of cardiac complications in 
COVID-19. Previous work has identified that ARDS (20%), arrhythmias 
(17%), shock (9%), and acute cardiac injury (7%) are common compi-
lations in COVID-19.1 Therefore, a better understanding of cardio-
vascular effects in SARS-CoV-2 infection is essential to mitigate poor 
prognosis in patients with COVID-19. The aim of this study is to con-
duct a comprehensive review of published studies on the electrophys-
iological effects of COVID-19. This is followed by a discussion on the 
underlying mechanisms, with proposals of preventative and therapeu-
tic strategies for treating cardiac arrhythmias in COVID-19 patients.
2  | COVID -19-REL ATED C ARDIAC INJURY: 
A POSSIBLE C AUSE FOR ARRHY THMIA?
The clinical course of SARS-CoV-2 infection is mostly character-
ized by respiratory tract symptoms, including fever, cough, pharyn-
godynia, fatigue, and complications related to pneumonia, such as 
acute respiratory distress syndrome and shock. Nevertheless, a brief 
case reported by Inciardi et al8 suggests that cardiac involvement 
may occur in patients with COVID-19 even without signs and symp-
toms of respiratory tract infection. Cardiac injury in the setting of 
COVID-19 has attracted extensive attention and follow-up research 
in the academic community.
Several studies have proved that SARS-CoV-2 infection can 
induce cardiac injury. Previous studies defined cardiac injury as 
the serum levels of cardiac biomarkers (eg, troponin I) were above 
the 99th percentile upper reference limit.1,2,9 Huang et al2 first re-
ported a 12% (5/41) incidence of acute cardiac injury in patients 
with COVID-19. A series of subsequently published studies con-
firmed the previous findings, the incidence of cardiac injury ranged 
from 7.2% to 28%.1,2,6,7,10,11 Moreover, the incidence of myocardial 
injury was higher in severe and critical cases, which ranged from 22% 
to 44%,1,2,9,12 compared to an incidence of approximately 2% to 4%1,2 
in less severe cases. Death cases (28% to 89%) had a conspicuously 
higher risk of cardiac damage than survivors (1% to 15%).5,6,9,10,12–15 
Several investigators have reported cardiac function and structural 
abnormalities in patients with SARS-CoV-2 infection, including acute 
heart failure (HF),3,10,16 takotsubo syndrome,17,18 viral myocarditis,19 
and acute myocardial infarction.10,20,21 Chen et al4 showed that ele-
vated cardiac troponin I (TnI) (Odd ratio [OR]: 26.9, 95%CI 4.1-177.2, 
P = .001) was the independent risk factor for COVID-19 severity. 
Furthermore, Shi et al6 first demonstrated that cardiac injury was in-
dependently associated with an increased risk of mortality in patients 
with COVID-19 (HR = 3.4, 95%CI 1.6-7.2, P < .001). Subsequently, 
Wang et al5 has drawn a similar conclusion.6 (Hazard ratio [HR]: 5.4, 
95%CI 2.4-12.1, P < .001), with the presence of myocardial injury 
being significantly associated with higher risk of in-hospital mortality 
among COVID-19 patients. Guo et al7 also found that the prognosis 
of patients with underlying cardiovascular disease (CVD) but without 
myocardial injury was relatively favorable, mortality during hospi-
talization was 7.6% (8/105) in patients without underlying CVD and 
normal troponin T (TnT) levels, 13% (4 of 30) in those with underlying 
CVD and normal TnT levels, 38% (6/16) for those without underlying 
CVD but elevated TnT levels, and 69% (25/36) for those with un-
derlying CVD and elevated TnTs. Together, data from these studies 
illustrate that the SARS-CoV-2 infection results in varying degrees of 
cardiac damage, which explains adverse outcomes observed.
Cardiac injury is a common condition among hospitalized pa-
tients with COVID-19. However, cardiac biomarker levels reflecting 
myocardial injury in COVID-19 patients are affected by numerous 
factors, such as infection, hypoxia, and renal function, there may 
also be false positives. It is therefore incomplete to evaluate the risk 
of cardiac adverse events in COVID-19 patients simply by cardiac 
biomarkers alone.
3  | COVID -19-REL ATED C ARDIAC 
ARRHY THMIA S
Full-genome sequencing and phylogenic analysis indicated that 
SARS-CoV-2 has features typical of the coronavirus family and dis-
tinct classified in the beta-coronavirus, belongs to the same genus as 
human severe acute respiratory syndrome coronavirus (SARS-CoV) 
and Middle East respiratory syndrome coronavirus (MERS-CoV).
In patients with SARS, tachycardia was the most common 
ECG abnormalities but usually self-limiting, the incidence ranged 
from 72%22; bradycardia was relatively less common, ranged from 
2% to 15%.22–24 ST-T changes and cardiac arrhythmias such as 
branch block, atrial fibrillation (AF), premature beats, QT interval 
prolongation, or even sudden cardiac death (SCD) were also seen in 
SARS patients.22–27 Cardiac arrhythmias, including variable tachyar-
rhythmias and severe bradycardia requiring temporary pacemaker 
implantation, occurred in 16% (11/70) MERS cases.28 More impor-
tantly, two MERS patients complicated with tachyarrhythmia were 
reported in 2014, one had hyperkalemia with associated ventricular 
tachycardia, and eventual cardiac arrest; the other had supraventric-
ular tachycardia later in the course of illness, both patients ended up 
with death.29 Thus, arrhythmias in SARS and MERS patients are not 
uncommon, and may lead to adverse outcomes.
Cardiac involvement has also been reported in patients with 
COVID-19, which can manifest as ECG abnormalities. COVID-19-
related cardiac arrhythmia was first described by Wang and col-
leagues,1 who reported a 17% (23/138) incidence of arrhythmias, 16 
of them were admitted to intensive care unit (ICU), accounting for 44% 
of the total number of ICU patients. A recent study reported a rate of 
only 26% of the patients showing normal ECGs.20 Lei et al30 reported 
24% of arrhythmias in COVID-19 patients, and 33% of patients admit-
ted to ICU developed arrhythmias. In fatal cases of COVID-19, 60% 
had arrhythmia,14 in addition, cardiac arrhythmias were independently 
associated with an increased risk of in-hospital death (11.5%, vs 5.6% 
among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33-2.86).31
Thus, arrhythmia should be regarded as one of the main com-
plications of COVID-19, and proactive arrhythmia monitoring and 
management is needed.
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3.1 | Tachycardia
COVID-19 patients have relatively increased fast heart rates (HR) 
ranging from 80 to 88 beats per minute (bpm) in sinus rhythm.1,5,20,32 
HR in patients treated in the ICU was faster than whom admitted in 
the general ward.1 Nonsurvivors showed significantly faster baseline 
heart rates on admission compared to survivors.10 Another study 
documented heart rate in 17 COVID-19 patients, and tachycardia 
was found in three patients (17.6%), one of those was a severe case, 
and two were critical cases.33 Moreover, two patients in the criti-
cal group had AF with elevated ventricular rates between 123 and 
160 bpm. One patient had persistent AF whereas the other did not 
have prior AF. Both passed away from COVID-19. The rising of HR in 
COVID-19 patients is disproportionate with the increase in the body 
temperature.33
Atrial tachyarrhythmias that had not been present on admission 
was recorded on a subsequent 12-lead ECG in 19 COVID-19 patients 
(19/115, 16.5%), all admitted to the MICU (27.5% of MICU patients), 
among them, atrial fibrillation in 12 patients, atrial flutter in 6 pa-
tients, and atrial tachycardia in 1 patient.34 Atrial tachyarrhythmias 
were common among patients with COVID-19 who required admis-
sion to an intensive care unit and were often followed by hemody-
namic deterioration.
In short, we have to pay attention to the tachycardias in the 
severe and critical COVID-19 patients. In addition to exacerbating 
the previous cardiomyopathy and conduction disorders, inducing ar-
rhythmia events, SARS-CoV-2 may also induce electrophysiological 
abnormalities in patients with no previous history of heart disease 
under a variety of mechanisms.
3.2 | Atrioventricular/intraventricular 
conduction block
Our recent work reported that the incidence of cardiac arrhythmias 
in COVID-19 patients ranged from 17% to 30%.1,20 Among these, 
atrioventricular/ventricular block (11.8%) was the highest incidence 
in arrhythmia, and the ratio exceeded sinus tachycardia (7.5%), 
sinus bradycardia (8%), atrial arrhythmias (7%), and ventricular ar-
rhythmias (4%).20 Complete heart block and severe left ventricular 
dysfunction were developed in a Child with COVID-19 Infection.35 
Another case from Iran also reported transient complete heart block 
in a patient with COVID-19,36 and a 21-year-old female patient’ ECG 
showed nonspecific intraventricular conduction delay and multiple 
premature ventricular complexes.19
3.3 | ST-T changes
In our report, ST-T changes were the most common ECG abnormal-
ity in COVID-19 patients, accounting for about 41% (38/93). Five 
of these patients were diagnosed with acute myocardial infarction 
(AMI).20 A recent case series showed 18 patients with COVID-19 
who had ST segment elevation in ECG, 13 (72%) patients died in the 
hospital (acute ST segment elevation myocardial infarction: n = 4; 
noncoronary myocardial injury: n = 9).21 A 61-year-old Hispanic 
male presented with a Brugada-type pattern ECG in right precordial 
leads, 2 days later he developed a brief episode of atrioventricular 
nodal reentrant tachycardia (AVNRT).37 A patient finally died within 
24 hours of the occurrence of multifocal ventricular tachycardia (VT) 
and ST segment elevation.38
3.4 | QT interal prolongation
Our study found a proportion of 13% (12/93) COVID-19 patients 
had prolonged QT interval, mean QT interval was 431 milliseconds 
(414-454 milliseconds).20 QT prolongation has previously been de-
scribed associated with various conditions (eg, inherited arrhythmia 
syndromes, myocarditis toxicity, metabolic disorders, certain drugs). 
Several antimicrobials that are currently used as potential thera-
peutic agents for COVID-19 have uncertain benefit, and yet may 
induce electrocardiographic QT prolongation with potential ven-
tricular pro-arrhythmic effects. These agents are chloroquine (CQ), 
hydroxychloroquine (HCQ), azithromycin, and lopinavir/ritonavir.39 
Recent evidence indicates significant QT prolongation in patients 
with COVID-19 receiving HCQ.40
For example, Borba and colleagues41 performed a parallel, 
double-blind, randomized clinical trial designed to assess the 
safety of CQ in dosages, they found that prolongation of QTc in-
terval was observed in 4 of 36 patients (11.1%) in the low-dose 
group (ie, 450 mg twice daily on day 1 and once daily for 4 days) 
and 7 of 37 patients (18.9%) in the high-dose group (ie, 600 mg 
CQ twice daily for 10 days); in addition, 2 patients in the high-
dose group (2.7%) experienced ventricular tachycardia, 60% (3/5) 
patients in the high-dose group with underlying heart disease 
died. Moreover, the patients who received HCQ with concurrent 
treatment of azithromycin were at high risk of greater changes in 
QTc,42 12% of them manifested critical QTc prolongation, and the 
combination caused greater prolongation than either drug alone.43 
Chorin et al44 observed QTc prolongation from a baseline average 
of 435 ± 24 milliseconds to 463 ± 32 milliseconds (P < .001), which 
was observed 3.6 ± 1.6 days after administration of HCQ + azith-
romycin therapy. In a subset of those patients (9/84, 11%), QTc was 
severely prolonged to >500 milliseconds, a known ECG marker of 
high risk of malignant arrhythmia and sudden cardiac death.44 
A greater proportion of patients receiving HCQ+azithromycin 
experienced cardiac arrest (15.5%) and abnormal ECG findings 
(27.1%), as did those in the HCQ alone group (13.7% and 27.3%, 
respectively), compared with azithromycin alone (6.2% and 16.1%, 
respectively).45
Certain antifungal drugs, glucocorticoids and certain anti-
arrhythmic drugs lead to prolonged QT intervals as well. If these 
medications are used, clinicians should monitor the patient for 
side effects, especially prolonged QTc interval by continuous ECG 
monitoring.
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3.5 | Malignant arrhythmias
COVID-19 patients generally have comorbidities that can increase 
the risk of serious arrhythmias. Malignant arrhythmias in COVID-19 
were first described by Guo and colleagues,7 who reported a 5.9% 
(11/187) incidence of malignant arrhythmias, including VT/ven-
tricular fibrillation (VF). Also, Du et al14 reported a large series of 
patients who died from COVID-19, and found that common cause 
of death in 7 of the 81 patients was cardiac arrest (8.64%), followed 
by acute coronary syndrome (4.94%) and malignant arrhythmias 
(2.47%). In adjusted models with those receiving HCQ or azithro-
mycin as comparison, cardiac arrest was more likely in patients re-
ceiving HCQ + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]; 
E-value = 1.31).45 SARS-CoV-2 can cause a variety of ECG changes, 
similar to SARS-CoV. By contrast, SARS-CoV-2 is more likely to in-
duce atrioventricular/intraventricular conduction block, QT interval 
prolongation, which may lead to a higher risk of malignant ventricu-
lar tachyarrhythmias.
At present, the ECG data of COVID-19 patients are limited, and 
there are discrepancies in terms of the reported rates of various ar-
rhythmia types among the different studies. This is likely the result 
of the nonhomogeneous characteristics of selected cases among 
studies, small sample size, region of origin, and the lack of continu-
ous ECG monitoring data. A single ECG evaluation is not comprehen-
sive. Dynamic ECG monitoring is required to better identify the type 
of arrhythmias. The available data indicate that the clinical course 
of COVID-19 develops rapidly, the ECG abnormalities detected 
during hospital stay may be used as a predictor for the severity 
of disease. If any critical COVID-19 patient has pathophysiologi-
cal changes similar to fulminant myocarditis, or ECG abnormalities 
such as conduction block, QT interval prolongation, and ventricu-
lar arrhythmia, they probably have a poor prognosis. It is therefore 
recommended that clinicians should perform a comprehensive eval-
uation through combining cardiac injury biomarkers, ECG dynamic 
changes and cardiac imaging, and be alert to life-threatening ventric-
ular arrhythmia storms.
4  | PUTATIVE MECHANISMS OF 
ARRHY THMIA S IN SARS- COV-2
A summary of the potential mechanisms by which cardiac arrhyth-
mias occur in SARS-COV-2 infections is shown in Figure 1.
First, SARS-COV-2 may induce injury to cardiomyocytes directly. 
SARS-COV-2 virus can be internalized after binding to the ACE2 
surface receptor on cell membranes, facilitated by the membrane 
binding proteases of transmembrane serine protease 2 (TMPRSS2) 
by cleaving the virus S protein.46,47 Once inside the cell, coronavi-
ruses replicate using a number of host molecular machinery, such as 
the NF-κB pathway.48 Activated NF-κB can affect mRNA expression 
of pore-forming subunit of fast transient outward potassium current 
(Ito,f), which can promote arrhythmia by affecting action potential 
(AP).49
Second, SARS-COV-2 may induce cell death. Recent studies have 
shown that after SARS-COV-2 infection of human bile duct epithe-
lial cells, the expression of genes related to "positive regulation of 
cell death" and "cell response to external stimulation" such as CD40, 
caspase recruitment domain family member 8 (CARD8) and serine/
thunine kinase 4 (STK4) were significantly up-regulated to induce 
cell death.50 We speculate that an analogous mechanism may oper-
ate in cardiomyocytes. Previous tissue visualization has revealed ir-
regular shape of the myocardium, darkened cytoplasm, mild fibrosis, 
and mild hypertrophy of the myocardium.51 Finally, myocardial dam-
age may reflect ongoing myocarditis and could induce arrhythmias 
by inducing electrical abnormalities.
Hypoxemia caused by respiratory dysfunction causes a rel-
atively hypoxic environment of the myocardium. Hypoxia can 
promote cardiomyocyte cell death and affect the function of ion 
F I G U R E  1   Potential Mechanisms of 
Cardiac Arrhythmias in COVID-19. SARS-
CoV-2: severe acute respiratory syndrome 
coronavirus-2; ACE2: Angiotensin-
converting enzyme-2; Angiotensin II: 
Ang II; Angiotensin (1-7): Ang (1-7); IK: 
potassium channel; INa: sodium current; 
ICa: Ca
2+ current; IL: Interleukin
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channels, leading to alterations in cardiac AP prolongation and/or 
repolarization, thereby promoting arrhythmogenesis.52 Hypoxia 
degrades the expression of the hERG, encoding pore-forming sub-
unit of the fast-activated delayed rectified potassium channel (IKr), 
by secreting calopersin, which reduces the IKr.
53 Moreover, late 
sodium current (INaL) is increased under hypoxia.
54 Together, ven-
tricular repolarization may be prolonged, leading to reentrant ar-
rhythmias. By contrast, a shortening in repolarization time caused 
by small-conductance Ca2+-activated K+ (SK) channels may also be 
pro-arrhythmic, especially where there is accompanying shorten-
ing in the effective refractory periods.55 This would be expected 
to reduce cardiac excitation wavelength in turn predisposing to 
reentrant activity.
Pro-inflammatory cytokines usually increased in COVID-19 pa-
tients, and cytokine storms have been reported in severe cases. These 
cytokines include IL-6 and IL-1β, IL-2, IL-8, IL-17, G-CSF, GM-CSF, 
IP10, MCP1, CCL3, and TNF-α.2,56–58 Acute administration of IL-6 
significantly increased L-type Ca2+ current (ICaL) density and higher 
amplitudes/durations of calcium transients in ventricular cardiomy-
ocytes.59 Long-term exposure to IL-6 significantly down-regulated 
the expression level of Ca2+-ATPase (SERCA2) gene in neonatal rat 
ventricular myocytes, which affected intracellular Ca2+ level.49 These 
studies suggest that IL-6 may affect cardiac AP in multiple ways. In 
addition, there was a significant correlation between IL-6 level and P 
wave index. Moreover, IL-6 can down-regulate atrial myocyte junc-
tion proteins causing atrial electrical remodeling.60 Thus, increased 
IL-6 in COVID-19 patients may affect AP and electrical conduction 
leading to arrhythmias. IL-1β extends the APD by reducing Ito cur-
rent, increasing CaMKII oxidation/phosphorylation and Ca2+ spark 
frequency, promoting arrhythmia.61 Also, IL-2 increases the peak INa 
density by increasing the transcriptional level of SCN3B, encoding the 
sodium channel,49,62 which leads to a decrease in the AP maximum 
upstroke velocity and ultimately promotes arrhythmia. TNF-α signifi-
cantly decreased the IKr density in ventricular myocytes by altering 
the type of reactive oxygen species, thereby prolonging APD.49,63 
In addition, TNF-α also reduced ICaL, intracellular calcium transients. 
Moreover, TNF-α may reduce the expression of SERCA2a by inducing 
the level of DNA methyltransferase.64 Therefore, TNF-α signaling is 
also an important inflammatory factor leading to arrhythmia.
Patients with COVID-19 often present with fever. In the patients 
with some underlying heart diseases, fever can trigger ventricular 
fibrillation.65,66 It may be related to ion channel mutations, such as 
SCN5A in Brugada syndrome.64 Besides, abnormal sodium current 
also plays an important role.67,68 In addition, fever can cause tach-
yarrhythmias in individuals without inherited heart disease. Its pres-
ence may alter the efficacy of sodium channel blockers in terms of 
their antiarrhythmic effects.69
SARS-COV-2 may induce myocardial injury by inhibiting the activ-
ity of ACE2. It is thought that ACE2 could be internalized and shed 
from the membrane surface diminishing function of ACE2 when SARS-
COV-2 binding to ACE2 to enter cells.68 The conversion of angiotensin 
II (Ang II) to Ang (1-7) may be reduced, which weakens the cardiovas-
cular protection effect of Ang (1-7) through the Mas receptor.70,71 
For example, Ang1-7 could change ICaL, Ito, expression of Kv4.3 po-
tassium channel, and Ca2+ channel to prevent AF ionic remodeling.72 
Besides, Ang II induces automatic activities by activating IP₃ receptors 
and Na⁺-Ca2+ exchanger in guinea pig pulmonary vein myocardium. In 
addition, chronic Ang II exposure induces ROS production by NOX2 
resulting in oxidative activation of CaMKII, further promotes SR- Ca2+ 
leakage, thus increasing the possibility of delayed after depolarization 
(DAD).73 Ang II induces membrane depolarization and activation of 
ICaL.
74 The accumulation of Ang II promotes myocardial fibrosis and 
cardiac remodeling. These will promote the occurrence of arrhythmias.
Many patients have disorders of coagulation and fibrinolytic sys-
tem, showing hypercoagulability of blood, and even disseminated 
intravascular coagulation (DIC).75 The effects of hypercoagulation 
on the myocardium, such as acute coronary syndrome,76 will be 
ischemia and hypoxia, leading to cardiac electrophysiological ab-
normalities. It has been changed that Na+-Ca2+ exchange, IK current, 
and phosphorylation of proteins in the sarcoplasmic reticulum.77,78 
Next, early and late depolarization, inducing ectopic beats, and the 
APD changed. All these will promote the development of reentrant 
arrhythmias such as malignant ventricular arrhythmia.64,77 In addi-
tion, acute left atrial ischemia led to ATP-sensitive potassium current 
(IKATP) conductor-dependent shortened APD, as well as sponta-
neous focal discharges and reentry loops.79 Chronic atrial ischemia/
infarction promoted atrial fibrillation by unprompted ectopy and 
sustained reentry.80
Administration of certain drugs may affect the electrophysi-
ological properties of the myocardium. For example, the recently 
controversial CQ and HCQ can cause prolongation of QT interval. 
In sinoatrial node (SAN) myocytes, HCQ decreased spontaneous 
action potential firing rate and the "funny" current (If), and it also 
affected ICaL and IKr.
81 These changes caused a delay in the depo-
larization, thus lowering the heart rate.76,82 In addition, azithromy-
cin can also affect the occurrence of AP promoting arrhythmias in 
cardiomyocytes. It is reported that azithromycin can inhibit ICaL, 
INa, and IKr current, causing bradyarrhythmia.
83 However, azithro-
mycin can increase INa currents in cardiomyocytes with chronic 
(24 hour) exposure.84 Moreover, azithromycin promoted the 
production of reactive oxygen species in cardiomyocytes, mito-
chondrial damage,85 inducing cardiac dysfunction and eventually 
arrhythmia occurs.
Together, a number of ion channels can be adversely affected in 
COVID-19, leading to alterations in cardiac conduction and/or repo-
larization properties, as well as calcium handling, which can predis-
pose to cardiac arrhythmogenesis.
5  | MANAGEMENT STR ATEGIES OF 
ARRHY THMIA S IN SARS- COV-2
5.1 | Clinical manifestations and diagnosis
Clinicians should be vigilant of potential rhythm disturbances in 
COVID-19. Palpitation has been reported as the initial symptom in 
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7% (10/137) of COVID-19 patients.86 Around 4% of COVID-19 pa-
tients have a prior history of cardiac arrhythmias and may be particu-
larly susceptible to further rhythm disorders.87 Therefore, there is a 
need to determine essential clinical information, such as a history of 
arrhythmias, unexplained syncope, family history of premature sud-
den cardiac death, as well as a detailed medication history, especially 
medications that can induce electrocardiographic QT prolongation, 
and baseline ECGs. Patients with underlying cardiovascular diseases 
require attention to their ECG abnormalities and potential risk of 
cardiac arrhythmias, so as to prevent adverse clinical events.
Baseline examination is necessary to evaluate the hospitalized 
patients or those who may be at higher risk for cardiac arrhythmias. 
If the patients with COVID-19 present with palpitation, dizziness, 
or even unexplained syncope, monitoring for cardiac arrhythmias 
should be performed. If baseline ECG examination reveals a mod-
erately prolonged QTc, optimization of medications and electrolytes 
may permit therapy. If the QTc is markedly prolonged, medications 
which further prolong it should be avoided, or expert consultation 
may permit administration with mitigating precautions.
ECG should be closely monitored for early warning and inter-
vention. During the pandemic, avoidance from nonessential testing, 
including serial ECG, reduces exposure of front-line medical work-
ers and other patients to infectious risk. Therefore, continuous 
ECG monitoring should be applied more in patients with COVID-19, 
especially in the patients with cardiac comorbidities. Some other ex-
perts suggest that it may be feasible to use a handheld ECG device 
and mobile continuous telemetry monitor (MCOT) as a QT screening 
tool in patients with COVID-19.88,89 Experts from National Center 
for Gerontology90 suggest that cardiologists and primary care phy-
sicians should pay attention to the following ECG indicators: the 
ST-T changes accompanied by continuously dynamic changes in 
two or more leads (I, II, aVF, V5) with R waves domination; new-on-
set sinus, atrioventricular conduction block, complete right or left 
bundle branch block, sinus arrest; continuous, coupled, pleomor-
phic, or multifocal premature contractions; atrioventricular reen-
trant tachycardia; atrial flutter/atrial fibrillation, QRS complex low 
voltage, abnormal Q waves and wide QRS complex (QRS > 120ms), 
continuous ECG monitoring if necessary. Attention should also be 
paid to whether patients have paroxysmal tachycardia or an increase 
in pulse rate that does not match the disease severity status. Early 
identification of high-risk ECG and arrhythmia, and timely interven-
tion are quite important. Bedside temporary cardiac pacemaker and 
defibrillator monitoring can be helpful.
5.2 | Prevention and treatment
Thus far, no specific antiviral drugs or vaccines have been confirmed 
to benefit COVID-19 except for symptomatic relief and supportive 
treatments. The treatment guidelines for COVID-19 published by 
The National Institutes of Health (NIH) determined that no drug(s) 
has been proven to be safe and effective for treating COVID-19 at 
present. Although reports have appeared in the medical literature 
asserting successful treatment of COVID-19 by multiple medica-
tions,41,91,92 additional evidence from ongoing clinical trials will be 
needed to identify the optimal treatment. Several antiviral agents 
and immunomodulating therapies are currently under clinical 
investigation.
Moreover, the COVID-19 Treatment Guidelines Panel recom-
mends against the use of the following drugs for the treatment of 
COVID-19: the combination of HCQ plus azithromycin (AIII) because 
of the potential for toxicities, except in the context of a clinical trial; 
Lopinavir/ritonavir (AI) or other human immunodeficiency virus 
(HIV) protease inhibitors (AIII) because of unfavorable pharmacody-
namics and negative clinical trial data.93
Tempered with concerns of increased risks of QT prolongation 
and development of TdP, which may be life-threatening, our poten-
tial therapeutic options are that it is necessary to discontinue unnec-
essary medications which may also increase the risk of arrhythmias. 
If this combination proves to be life-saving for COVID-19 patients, 
monitoring the QT interval to allow patients to receive combination 
therapies will be critical.
Certainly, the use of combination therapies with azithromycin 
and CQ or HCQ in high-risk patients must be carefully weighed 
against the risks. The higher dosage of CQ (ie, 600 mg CQ twice 
daily for 10 days) should not be recommended for critically ill pa-
tients with COVID-19 because of its potential safety hazards, espe-
cially when taken concurrently with azithromycin and oseltamivir.41 
The late sodium channel-blocking drugs like mexiletine have been 
proposed to be used if the QT interval prolongs.94 A temporary 
transvenous pacemaker may be necessary to overdrive pace if the 
patient is bradycardia with premature ventricular complexes. Careful 
attention to serum electrolytes, heart rate, and monitoring of QTc 
intervals may allow administration of a full course of these drugs.
Prevention or treatment of arrhythmias in COVID-19 patients 
should include optimization of supportive treatments, including 
bed rest, maintaining water and electrolyte balance, medication or 
physical cooling in patients with fever, oxygen supplementation in 
patients with hypoxia or dyspnea, and noninvasive or invasive ven-
tilator support treatment where indicated. For patients with sinus 
tachycardia, diltiazem or ivabradine may be used for rate manage-
ment.90 Diltiazem, propafenone, or verapamil were also considered 
first in patients with atrial premature beats or tachycardia without 
cardiac disease.95 Beta-blockers may promote bronchial smooth 
muscle spasm and induce asthma adverse reactions, should be 
used with caution in patients with COVID-19 combined with sinus 
or atrial tachycardia. If the patient shows sustained VT, intrave-
nous infusion of amiodarone and other antiarrhythmic medications 
may be given, electrical defibrillation can be used if it necessary. 
If VF occurs, cardiopulmonary resuscitation should be initiated 
and defibrillation should be initiated immediately. If patients with 
severe bradycardia resulting in dizziness, amaurosis, syncope and 
other symptoms, can be given atropine, isoproterenol, and other 
drugs to increase the heart rate or a temporary venous pacemaker 
may be placed. In anticipation of the predicted surge of patients 
infected with COVID-19 and the need to rationally utilize personal 
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protective equipment (PPE) while continuing to provide urgent 
and emergency cardiac interventions, adequate provision of PPE 
is just the first step.
6  | CONCLUSIONS
Outbreaks of COVID-19 threaten public health but the associated extra-
pulmonary manifestations and their prolonged consequences are often 
overlooked. Previous reports reveal that cardiac arrhythmias are one of 
the common complications associated with COVID-19, which may some-
times be life-threatening. We would suggest that front-line clinicians 
monitor cardiac rhythm as part of the routine care, and the data may shed 
light on whether COVID-19-related arrhythmic complications is an inde-
pendent predictor of adverse outcomes. Early diagnosis and timely treat-
ment to reduce mortality is of crucial importance. Herein, we summarize 
potential pharmacological and interventional strategies for dealing with 
such problem. Several medications are currently being tested for their an-
tiviral actions, with potential side effects such as QT prolongation.
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